-

GeneDx to Participate in Upcoming Investor Conference

STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in the Piper Sandler 36th Annual Healthcare Conference from December 3-5 in New York City, NY. Management will participate in a fireside chat on Tuesday, December 3, 2024, at 1:00 p.m. ET.

Live and archived webcasts will be available on the “Events” section of the GeneDx investor relations website at ir.genedx.com/news-events/events.

About GeneDx

At GeneDx (Nasdaq: WGS), we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world’s largest rare disease data sets, our industry-leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. For more information, please visit genedx.com and connect with us on LinkedIn, X, Facebook, and Instagram.

Contacts

Investor Relations:
investors@GeneDx.com

Media:
press@GeneDx.com

GeneDx

NASDAQ:WGS

Release Summary
GeneDx (Nasdaq: WGS) today announced that company management will participate in the Piper Sandler 36th Annual Healthcare Conference.
Release Versions

Contacts

Investor Relations:
investors@GeneDx.com

Media:
press@GeneDx.com

More News From GeneDx

GeneDx Reports First Quarter 2026 Financial Results and Updates Full-Year Outlook

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx reported first quarter financial results and business highlights, including 34% year-over-year volume growth in exome and genome testing....

GeneDx to Report First Quarter 2026 Financial Results on Monday, May 4, 2026

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today announced it will release financial results for the first quarter of 2026 after the market closes on Monday, May 4, 2026....

Landmark Study Shows Average Cost Savings of $80,000 Per Child and Overall Improved Health Outcomes Following GeneDx Exome and Genome Testing

GAITHERSBURG, Md.--(BUSINESS WIRE)--Landmark Study Shows Average Cost Savings of $80,000 Per Child and Overall Improved Health Outcomes Following GeneDx Exome and Genome Testing...
Back to Newsroom